
PROGRESS Reducing Recurrent Stroke Risk After Stroke or TIA
The PROGRESS trial showed that a perindopril-based BP-lowering regimen reduced recurrent stroke by 28% and major vascular events by 26% in patients with prior stroke or TIA.
Content exclusive for connected users. Please sign in or register to access more.
Already have an account?
Sign inNew here?
Create account